Tirzepatide vs Semaglutide

Tirzepatide wins for:

• Superior potency: Higher average and maximum weight loss (up to ~21% at 15 mg/wk, vs. ~15–19% for sema) validated in head-to-head and phase III data.
• Faster time-to-effect and more pronounced suppression of appetite, especially at physique-geared doses (>2.5 mg/wk).
• Lower food noise for users struggling with severe hunger or large caloric deficits that defeat semaglutide alone.

Semaglutide wins for:

• Better GI tolerability and a much less punishing nausea profile at equivalent weight loss (especially <1 mg); thus, easier long-term use at moderate doses.
• Greater clinical maturity (safety data, sourcing, protocols) and much wider vendor network.
• Ideal for users who hit their floor or experience intolerable GIP agonist side effects on tirzepatide.

Pick Tirzepatide if:

• You want maximal fat loss per week: contest prep, very aggressive cuts, or need to break a hard plateau.
• Semaglutide isn't killing appetite enough, or you're running a high-surplus environment (test + GH + slin) and need deeper suppression.
• You need faster onset or are short on time for a hard cut (event coming up, fast transformation cycle).
• Resistant obesity, metabolic syndrome, or prior GLP-1 tolerance blunted semaglutide response.
• Fine with titration and can manage side effect mitigation (GI protocol, lower starting doses).

Pick Semaglutide if:

• You want smoother, side effect-minimized appetite control for maintenance, recomps, or mild-to-moderate cuts.
• Tried tirzepatide and dropped out due to GIP-induced nausea or GI side effects.
• Plan indefinite or cruise use; prioritizing sustainability and sourcing ease over cutting-edge fat loss.
• Want the most established compound with maximal literature on long-term safety and interactions.
• Need to keep cost and access straightforward (more vendors, established sourcing, better generics).